Clinical trials: Graft Failure
End Stage Renal Disease, Renal Transplant Rejection
MRI in Renal Transplantation
Renal transplantation is the optimal method of treatment for end stage kidney disease however median lifespan of a kidney transplant is around 15 years.
- Conditions
- End Stage Renal Disease, Renal Transplant Rejection, Kidney Transplant Failure and Rejection, Chronic Kidney Diseases
- Trial name
- TransRASL (NCT03705091)
- Testing
- Magnetic resonance imaging
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- NHS Greater Glasgow and Clyde
Lung Transplant Failure
Respiratory Physiotherapy as a Tool to Increase the Number of Solid Organ Donors
The main objective of the project is to determine the variation of PaO2 / FiO2 (PaFi) after the use of mechanical insufflation-exsufflation (MI-E) or mechanical cough assistant in the donor in brain death (DBD) and in the…
- Trial name
- NCT06202859
- Testing
- MIE
- Where
- Spain
- Volunteers
- 160 people
- Sponsor
- Vall d'Hebron Institute Research
Liver Failure
Hepatitis C Virus (HCV) Positive Liver Grafts in HCV Negative Recipients
To provide proof-of-concept data on the efficacy/safety of transplanting HCV positive donor grafts in HCV sero-negative liver recipients who are currently listed.
- Trial name
- NCT03650920
- Testing
- Liver Transplantation
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- Loma Linda University
Kidney Transplant; Complications, Kidney Transplant Failure
Can Dapagliflozin Preserve Structure and Function in Transplanted Kidneys?
The goal of this clinical trial is to look at the effect of SGLT2 (Sodium glucose transporter 2) inhibition in patients receiving a kidney-transplant 6 weeks earlier at Oslo University hospital. Rikshospitalet.
- Conditions
- Kidney Transplant; Complications, Kidney Transplant Failure, Renal Failure
- Trial name
- DEAKTransplant (NCT05788276)
- Testing
- Dapagliflozin 10mg Tab
- Where
- Norway
- Volunteers
- 330 people
- Sponsor
- Oslo University Hospital
Leukemia, Myeloid, Chronic, BCR-ABL Positive
Low-dose Nilotinib and Imatinib Combination in Chronic Myeloid Leukemia Patients, With Failure, Suboptimal Response or Treatment Intolerance
The purpose of this study is to determine if low-dose imatinib and nilotinib combination, will improve treatment results in CML patients with failure, suboptimal response or intolerance to imatinib therapy.
- Trial name
- NCT01819389
- Testing
- Imatinib and Nilotinib
- Where
- Mexico
- Volunteers
- 10 people
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez